Pure red cell aplasia due to treatment with epoietin beta: first case report of PRCA from Poland.
Pure red cell aplasia (PRCA) emerged recently as the potentially life-threatening condition secondary to anti-Epo antibodies. Vast majority of cases were reported from Western European countries and were secondary to subcutaneous injections of Epoietin alpha. Here we describe possibly for the first time in the literature the case of PRCA from Poland or even Central and Eastern Europe in patient treated exclusively with Epoietin beta from multi-dose vial. In the last section of the paper the current epidemiological, diagnostic and therapeutic aspect of PRCA were discussed.
Sułowicz
Władysław
W
Department of Nephrology, Jagiellonian University, Cracow, Poland. wladsul@mp.pl
Bentkowski
Wacław
W
Stompór
Tomasz
T
Gross
Johann
J
Biłyk
Anna
A
Rudzki
Zbigniew
Z
D000368:Aged; D000740:Anemia / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology; D001856:Bone Marrow Examination / Q000379:methods; D004921:Erythropoietin / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011044:Poland; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced* / Q000175:diagnosis* / Q000276:immunology; D006435:Renal Dialysis
D001323:Autoantibodies; D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin